{"id":"raf1","name":"CRAF (RAF1)","symbol":"RAF1","route":"/targets/raf1/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9829","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132155","uniprot":"https://www.uniprot.org/uniprotkb/P04049/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P04049","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1906","open-targets":"https://platform.opentargets.org/target/ENSG00000132155","civic":"https://civicdb.org/genes/5894/summary","oncokb":"https://www.oncokb.org/gene/RAF1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAF1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=RAF1","depmap":"https://depmap.org/portal/gene/RAF1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000132155-RAF1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5894","omim":"https://www.omim.org/entry/164760"}],"products":[{"id":"regorafenib","name":"Regorafenib","status":"approved","modality":"Small-molecule multi-kinase inhibitor","route":"/drugs/regorafenib/"}],"trials":[{"id":"nct03829462","name":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients","nct":"NCT03829462","phase":"3","status":"active"},{"id":"imblaze370","name":"IMblaze370","nct":"NCT02788279","phase":"3","status":"negative"},{"id":"resorce","name":"RESORCE","nct":"NCT01774344","phase":"3","status":"positive"},{"id":"concur","name":"CONCUR","nct":"NCT01584830","phase":"3","status":"positive"},{"id":"correct","name":"CORRECT","nct":"NCT01103323","phase":"3","status":"positive"},{"id":"grid","name":"GRID","nct":"NCT01271712","phase":"3","status":"positive"},{"id":"nct07730489","name":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F","nct":"NCT07730489","phase":"3","status":"planned"},{"id":"nct06199973","name":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, ","nct":"NCT06199973","phase":"3","status":"active"},{"id":"nct05794971","name":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases","nct":"NCT05794971","phase":"3","status":"recruiting"},{"id":"nct05425940","name":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","nct":"NCT05425940","phase":"3","status":"active"},{"id":"nct07134205","name":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer","nct":"NCT07134205","phase":"3","status":"planned"},{"id":"nct05462613","name":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","nct":"NCT05462613","phase":"2/3","status":"recruiting"},{"id":"gbm-agile","name":"GBM AGILE","nct":"NCT03970447","phase":"platform","status":"recruiting"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"regobone","name":"REGOBONE","nct":"NCT02389244","phase":"2","status":"positive"},{"id":"nct06829355","name":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\"","nct":"NCT06829355","phase":"2","status":"recruiting"},{"id":"nct06887218","name":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","nct":"NCT06887218","phase":"2","status":"recruiting"},{"id":"nct06246643","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","nct":"NCT06246643","phase":"2","status":"active"},{"id":"nct02955940","name":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","nct":"NCT02955940","phase":"2","status":"active"},{"id":"nct05057052","name":"Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis","nct":"NCT05057052","phase":"2","status":"recruiting"},{"id":"nct06949982","name":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Co","nct":"NCT06949982","phase":"2","status":"recruiting"},{"id":"nct06558773","name":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.","nct":"NCT06558773","phase":"2","status":"recruiting"},{"id":"nct05985109","name":"KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer","nct":"NCT05985109","phase":"2","status":"recruiting"},{"id":"nct07310173","name":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","nct":"NCT07310173","phase":"2","status":"recruiting"},{"id":"nct06911684","name":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.","nct":"NCT06911684","phase":"2","status":"recruiting"},{"id":"nct07071961","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","nct":"NCT07071961","phase":"2","status":"recruiting"},{"id":"nct05963490","name":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","nct":"NCT05963490","phase":"2","status":"recruiting"},{"id":"nct06425133","name":"Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers","nct":"NCT06425133","phase":"2","status":"recruiting"},{"id":"nct07213570","name":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","nct":"NCT07213570","phase":"2","status":"recruiting"},{"id":"nct04701476","name":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","nct":"NCT04701476","phase":"2","status":"recruiting"},{"id":"nct07040228","name":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer","nct":"NCT07040228","phase":"1/2","status":"recruiting"},{"id":"nct07750041","name":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer","nct":"NCT07750041","phase":"1/2","status":"planned"},{"id":"nct06047379","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","nct":"NCT06047379","phase":"1/2","status":"recruiting"},{"id":"nct04781192","name":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers","nct":"NCT04781192","phase":"1/2","status":"active"}],"pathways":[],"companies":["bayer"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}